Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial - Rini, B I; Escudier, B; Tomczak, P (J Clin Oncol 2011)
(suppl; abstr. 4503)